Cargando…
Gene therapy in haemophilia: literature review and regional perspectives for Turkey
Haemophilia is an X-linked lifelong congenital bleeding disorder that is caused by insufficient levels of factor VIII (FVIII; haemophilia A) or factor IX (FIX; haemophilia B) and characterized by spontaneous and trauma-related bleeding episodes. The cornerstone of the treatment, factor replacement,...
Autores principales: | Kavaklı, Kaan, Antmen, Bülent, Okan, Vahap, Şahin, Fahri, Aytaç, Selin, Balkan, Can, Berber, Ergül, Kaya, Zühre, Küpesiz, Alphan, Zülfikar, Bülent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310332/ https://www.ncbi.nlm.nih.gov/pubmed/35898436 http://dx.doi.org/10.1177/20406207221104591 |
Ejemplares similares
-
Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study
por: Kavaklı, Kaan, et al.
Publicado: (2021) -
S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023) -
Rare Coagulation Disorders: A Retrospective Analysis of 156 Patients in Turkey
por: Fışgın, Tunç, et al.
Publicado: (2012) -
S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
por: Kenet, Gili, et al.
Publicado: (2023) -
Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
por: Ay, Yilmaz, et al.
Publicado: (2010)